Chair

Chair

Sylwia Kaeding, MD

Medical College of Wisconsin

Predicting Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Patient Without Diabetes, Is FIB4 Still the Best?

Natalie N Nguyen-Jones, MD

University of Colorado Medicine, Department of Medicine

Hepatocyte Period 1 Prevents Diet-Induced Obesity Through Inhibiting PP2A Independent of The Core Circadian Clock

Jiameng Sun

Washington University in St. Louis

Liver lipid droplet cholesterol content is a key determinant of metabolic dysfunction-associated steatohepatitis

Ikki Sakuma, MD, PhD

Yale University

Comparative Analysis of Glucagon Receptor Agonists vs Resmetirom in MASLD and MASH:Network Meta-Analysis of Clinical Trials

Celina Andonie

Faculty of Medicine, Al Quds University

A Multinational Study of Serum Metabolomics and Lipidomics in the Pathophysiology and Non-invasive Diagnosis of Metabolic Dysfunction-Associated Steatotic Liver Disease

Konstantinos Stefanakis, MD

Harvard Medical School

Developmental Programming: Origin of MASLD in a Sheep Model of Polycystic Ovary Syndrome and Impact of Postnatal Obesity on its Severity

Katherine M Halloran, PhD

University of Kentucky

The Overlapping Burden of NAFLD and Associated Endocrine Disorders: A Nationwide 25-Year Analysis of Mortality Trends in the United States

Ashraf Ahmed

Yale University, Bridgeport Hospital